Press Coverage

In 2024, Bright Pink made a $3.5 million legacy gift to establish the Bright Pink Preventive Risk Outreach And Cascade Testing (PROACT) Program at Stanford Medicine.

Led by Stanford physicians Dr. Allison Kurian and Dr. Jennifer Caswell-Jin, in collaboration with the University of Michigan, the Bright Pink PROACT Program aims to democratize access to cascade testing.

This type of genetic testing, which identifies hereditary mutations like BRCA1 and BRCA2 and extends testing to family members, holds enormous potential to save lives from breast and ovarian cancer, yet remains significantly underutilized, with only one-third of those at risk taking action.

University of Michigan and Stanford University develop digital platform to help families with inherited cancer risk.

A partnership between the University of Michigan and Stanford University is reshaping cancer prevention. With a transformative gift from Bright Pink, a national nonprofit organization that helped to shape the breast and ovarian health landscape for nearly two decades, the two university partners are developing a novel approach to cancer prevention.

Bright Pink was founded by U-M College of Literature, Science, and the Arts alumnus Lindsay Avner Kaplan (A.B. 2005). Together, the partners aim to empower families to understand and communicate about inherited cancer risk and help save lives through expanding access to critical prevention resources.

The Bright Pink Preventive Risk Outreach And Cascade Testing (PROACT) Program at Michigan Medicine is a digital platform that helps families with inherited cancers share vital information and access affordable at-home genetic testing.

The goal of PROACT is to save lives by enabling people to learn about their cancer risk status and take informed action, such as lifestyle changes, adopting earlier or more frequent screenings, or pursuing risk-reducing surgery, to protect themselves from cancer.